Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease.

• Drug: UK-432,097
  
  Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
• Drug: Placebo
  
  Capsules containing 100% lactose administered BID using an atomizer device

• Experimental: 150mcg, 450mcg or 1350mcg
  
  Active treatment given BID via a double pin monodose capsule inhaler device
  Intervention: Drug: UK-432,097
• Placebo Comparator: Placebo
  
  Placebo treatment given BID via a single pin monodose inhaler device
  Intervention: Drug: Placebo

Inclusion Criteria:

• Patients with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD) and who meet the criteria for Stage II-III disease
• Patients must have a smoking history of at least 10 pack-years
• Patients must have stable disease for at least 1 month prior to screening.

Exclusion Criteria:

• More than 2 exacerbations of COPD in the preceding year
• History of a lower respiratory tract infection or significant disease instability during the month proceding screening or during the time between screen and randomization.
• History or presence of respiratory failure, cor pulmonale or right ventricular failure